TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Trial Evaluating a 13-valent Pneumococcal Conjugate Vaccine Given With Diphtheria, Tetanus, and Acellular Pertussis Vaccine (DTaP) in Healthy Japanese Infants

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Male or female subjects between 3 to 6 months of age at the enrollment.~* Available for the entire study period and whose parent/legal guardian can be reached by telephone.~* Healthy infant as determined by medical history, physical examination, and judgement of the investigator.~Exclusion Criteria:~* Previous vaccination with licensed or investigational pneumococcal, diphtheria, tetanus, or pertussis vaccines.~* A previous anaphylactic reaction to any vaccine or vaccine-related component.~* Bleeding diathesis or condition associated with prolonged bleeding time that would contraindicate any type of injection.~* History of culture-proven invasive disease caused by S pneumoniae (eg, meningitis, bacteremia, osteomyelitis, arthritis).~* Infant who is a direct descendant (child, grandchild) of the study site personnel.

- Gender: ALL
- Minimum Age: 3 Months
- Maximum Age: 6 Months
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): Experimental
- 2 (Type: ACTIVE_COMPARATOR): Active comparator
- 3 (Type: ACTIVE_COMPARATOR): Active comparator

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Group-Based Behavioral Therapy Combined With Stimulant Medication for Treating Children With Attention Deficit Hyperactivity Disorder and Impaired Mood

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* ADHD combined subtype with evidence of depressive or manic-like symptoms, as assessed by CDRS, YMRS, and Washington University in St. Louis Kiddie Schedule for Affective Disorders and Schizophrenia, that persist after stimulant treatment~Exclusion Criteria:~* Full Scale IQ less than 80~* Current seizure disorder or history of seizures requiring treatment or other significant neurological problems~* History of other medical problems for which stimulant treatment may involve considerable risk, including cardiac arrhythmias, hypertension, Tourette's disorder, or history of severe tic exacerbations caused by stimulant exposure (Note: child with uncomplicated tic disorders or a family history of tic disorders will not be excluded as stimulants are well tolerated in a majority of such cases)~* Meets full criteria for Type I or II bipolar disorder or any child manifesting mood symptoms (manic or depressive), such as significant suicidal ideation or psychotic symptoms that require emergent pharmacological treatment or hospitalization~* History or concurrent diagnosis of any of the following disorders: pervasive developmental disorder, schizophrenia or other psychotic disorders, post-traumatic stress disorder, sexual disorders, organic mental disorder, or eating disorder~* No longer manifests impairing manic/depressive symptoms after stimulant therapy based on CDRS-R greater than 27 or YMRS greater than 11 with Clinical Global Impressions-Severity 3 or greater

- Gender: ALL
- Minimum Age: 7 Years
- Maximum Age: 11 Years
- Healthy Volunteers: f

Study Arms:
- 1 (Type: ACTIVE_COMPARATOR): Participants will receive stimulant medication therapy and referrals to community-based psychosocial treatments.
- 2 (Type: EXPERIMENTAL): Participants will receive stimulant medication therapy and group-based behavior therapy.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Management of Decompensated HCV Cirrhotic Patients

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* chronic active HCV proved by the positivity of HCV RNA, elevated transaminases.~* CTP score was \>9, MELD score was \<29~* Decompensated cirrhosis with frequent hepatic encephalopathy (HE) or difficult to treat ascites~Exclusion Criteria:~* exposure to previous antiviral therapy~* hepatocellular carcinoma~* other causes of liver diseases or mixed causes (excessive alcohol consumption, autoimmune liver disease)~* previous liver transplantation.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: t

Study Arms:
- cases (Type: ACTIVE_COMPARATOR): patients with decompensated cirrhosis~treated with Sofosbuvir 400 mg (Sovaldi) + Daclatasvir 60mg (Daklinza) + Ribavirin 200 mg (Rebetol)
- control group (Type: PLACEBO_COMPARATOR): the control group treated with liver support including silymarin 140 + phytomenadione 10 mg + lasilactone 50 mg + albumin infusion

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Enamel Remineralization Potential of Dentifrices in Situ

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE4
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Good general health with (in the opinion of the investigator) no clinically significant and relevant abnormalities of medical or oral health.~* No current active caries or periodontal disease that may compromise the study or health of the subject.~* All restorations in a good state of repair~* Currently wearing a removable mandibular partial denture with sufficient room in the posterior buccal flange area to accomodate two enamel specimens required dimensions 12 x 7 mm.~* Willing to have their denture modified to accomodate enamel test specimens~* Willing and capable of wearing removable mandibular partial dentures 24 hours per day during the treatment periods.~* Salivary flow rate in the range of normal values (unstimulated whole saliva flow rate greater than or equal to 0.2 mL/ minute; gum base stimulated whole saliva flow rate greater than or equal to 0.8 mL/minute.~Exclusion Criteria:~* Individuals currently taking antibiotics, or who have taken antibiotics within 30 days prior to the first treatment visit.~* Current active caries or periodontal disease that may compromise the study or health of the subject.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: t

Study Arms:
- Fluoride Toothpaste 1 (Type: EXPERIMENTAL): Fluoride toothpaste containing sodium fluoride (NaF)
- Fluoride Toothpaste 2 (Type: EXPERIMENTAL): Fluoride toothpaste containing stannous fluoride (SnF) and NaF.
- Fluoride Toothpaste 3 (Type: EXPERIMENTAL): Fluoride toothpaste containing sodium monofluorophosphate (NaMFP) and NaF.
- Reference Dentifrice (Type: ACTIVE_COMPARATOR): Low fluoride toothpaste containing NaF

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety of Colesevelam in Pediatric Patients With Genetic High Cholesterol

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE4
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Male or female patients~* Ages 10 to 17 years inclusive~* Diagnosis of heterozygous familial hypercholesterolemia~* On a stable dose of statin monotherapy or are treatment naive to lipid- lowering agents~* On a low-cholesterol diet~Exclusion Criteria:~* Patients should not have serious concomitant conditions that could interfere with the analysis of the results or that could interfere with the well-being of the patients

- Gender: ALL
- Minimum Age: 10 Years
- Maximum Age: 17 Years
- Healthy Volunteers: f

Study Arms:
- high dose colesevelam (Type: EXPERIMENTAL): colesevelam HCl 3.750 g
- Low dose colesevelam (Type: EXPERIMENTAL): Low dose colesevelam 1.875 g
- placebo (Type: PLACEBO_COMPARATOR): placebo comparator

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study of Neurophysiologically Based Occupational Therapy Intervention (NBOTI) for Feeding in the NCCU.

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* A mixed group of infants included preterm to term age infants at various levels of risk (per diagnoses) for central nervous system damage and feeding problems; but not small for dates by obstetrical dating and neurological exam, or genetic anomaly. Occupational therapy intervention began per physician approval; when patients were medically stable, and with consistent levels of blood oxygen and stable levels of supplemental oxygen (FiO2), and who were off of medication for paralysis and weaned from sedation. Historical matched control participants were matched with the intervention group participants who have the same diagnosis, gestational age, and neonatal complications.~Exclusion criteria included infants with specific cardiac distress syndrome, genetic anomalies, and small for dates.

- Gender: ALL
- Minimum Age: 29 Weeks
- Maximum Age: 44 Weeks
- Healthy Volunteers: f

Study Arms:
- Intervention Group (Type: EXPERIMENTAL): The infants in the intervention group were problem eaters with various diagnosis
- Matched Historical Comparison Group (Type: NO_INTERVENTION): The matched historical comparison group were also problem eaters and these infants did not receive the neurophysiologically based occupational therapy Intervention.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Rasagiline in the Treatment of Persistent Negative Symptoms of Schizophrenia

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Subjects will meet DSM-IV criteria for schizophrenia or schizoaffective disorder.~* Current treatment with one or more second generation antipsychotics, except ziprasidone~* On same second generation antipsychotic(s)for at least 56 days~* On same dose of second generation antipsychotic(s)for at least 30 days~* 22-item SANS: Total score (i.e.all items minus global items and poverty of content of speech)greater than 20 or global Rating of Affective Flattening greater than or equal to 3 or global Rating of alogia greater than or equal to 3~* BPRS: Sum of the four positive symptom items less than or equal to 16 (items 4,11,12,15)~* BPRS: Sum of the four Anxiety/Depression Factor items less than or equal to 14 (items 1,2,5,9)~* Simpson-Angus Scale: Total score less than or equal to 8~Exclusion Criteria:~* DSM-IV Major Depressive Disorder within last 6 months~* Current treatment with ziprasidone~* DSM-IV diagnosis of alcohol or substance dependence within the last 6 months~* DSM-IV criteria for alcohol or substance abuse within the last month~* evidence of illicit substance use, as identified with urine toxicology screen~* History of an organic brain disorder, mental retardation,epilepsy, or a medical condition, whose pathology or treatment could alter the presentation or treatment of schizophrenia or significantly increase the risk associated with the proposed treatment protocol. See those listed below~* Uncontrolled hypertension defined as BP exceeding 145/90 on 3 consecutive readings despite adequate treatment, pheochromocytoma, melanoma, hepatic insufficiency~* Pregnancy or lactation in females~* Pheochromocytoma~* Melanoma~* Hepatic insufficiency

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 64 Years
- Healthy Volunteers: f

Study Arms:
- Rasagiline (Type: ACTIVE_COMPARATOR): Treatment with Rasagiline
- Inactive pill (Type: PLACEBO_COMPARATOR): Treatment with Placebo

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Comparison of 2.0 mg/kg Sugammadex and Neostigmine at Reappearance of T2 in Chinese and European Subjects (Study 19.4.324)(P05768AM1)(COMPLETED)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE3
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~-Subjects who are willing to provide informed consent; be between 18 and 64 years old; are American Society of Anaesthesiology (ASA) class 1-3 (extremes included); scheduled for elective surgery under general anesthesia, allowing stable neuromuscular monitoring, which requires neuromuscular blockade using rocuronium; be compliant with the dose/visit schedules, and use an accepted method of contraception (if applicable).~For China only: Subjects of Chinese descent born in China, never emigrated out of China and have a Chinese home address. For Europe only: Subjects of Caucasian descent born in Europe, never emigrated out of Europe and have a European home address.~Exclusion Criteria:~-Subjects with expected difficult intubation, neuromuscular disorders affecting neuromuscular blockade, significant renal/hepatic dysfunction, use of a tourniquet, (family) history of malignant hyperthermia, allergy to general anesthesia medications, contraindication to study drugs, breast feeding, pregnant, participation in previous or new trials, a clinically significant condition that may interfere with the trial, or membership in the (family of) study/sponsor staff.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 64 Years
- Healthy Volunteers: f

Study Arms:
- Sugammadex in Caucasian Subjects (Type: EXPERIMENTAL): At reappearance of T2 after the last dose of rocuronium, 2.0 mg.kg-1 sugammadex was administered.
- Neostigmine in Caucasian Subjects (Type: ACTIVE_COMPARATOR): At reappearance of T2 after the last dose of rocuronium, 50 μg.kg-1 neostigmine (combined with 10-20 μg.kg-1 atropine, in a ratio ranging from 2.5:1 to 5:1) was administered.
- Sugammadex in Chinese Subjects (Type: EXPERIMENTAL): At reappearance of T2 after the last dose of rocuronium, 2.0 mg.kg-1 sugammadex was administered.
- Neostigmine in Chinese Subjects (Type: ACTIVE_COMPARATOR): At reappearance of T2 after the last dose of rocuronium, 50 μg.kg-1 neostigmine (combined with 10-20 μg.kg-1 atropine, in a ratio ranging from 2.5:1 to 5:1) was administered.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Testing Self-Control as a Behavior Change Mechanism to Increase Physical Activity

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: SINGLE
- Phase: EARLY_PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* between 35-65 years of age~* fluent in English~* fit enough to walk for at least 20 min at a time~* owns a smartphone~Exclusion Criteria:~* experienced a fall or heart problem/condition in the last 6 months~* is currently participating in an exercise program to increase physical activity~* is already physically active (physically active = exercise regularly 3 times per week, or more for at least 30min)~* was advised by a doctor to not walk due to health conditions

- Gender: ALL
- Minimum Age: 35 Years
- Maximum Age: 65 Years
- Healthy Volunteers: t

Study Arms:
- Self-control treatment group (Type: EXPERIMENTAL): The self-control treatment group will wear a Fitbit step counter across 8 weeks. In addition, they will use the MindHike smartphone application across 8 weeks. Each day, the app sends the a reminder to wear the Fitbit as well as a short interventional input targeting self-control.
- Control group (Type: ACTIVE_COMPARATOR): The control group will wear a Fitbit step counter across 8 weeks. In addition, they will use the MindHike smartphone application across 8 weeks. Each day, the app sends the a reminder to wear the Fitbit.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Safety and Potential Bioactivity of CLBS16 in Patients With Coronary Microvascular Dysfunction and Without Obstructive Coronary Artery Disease

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Men or women age ≥18~* History of and currently experiencing angina at least 3 times per week~* No obstructive coronary artery disease~* On stable medical therapy for 30 days prior to enrollment~* Must agree to use a reliable and acceptable method of contraception for the duration of participation~* Written informed consent~Exclusion Criteria:~* Myocardial infarction within 90 days~* Prior evidence of obstructive heart disease including PCI or CABG (or planned PCI or CABG)~* Diagnosis of other specific cardiac disease~* Must meet LVEF and GFR requirements~* Current use of coumadin or DOACs~* Hypersensitivity to G-CSF, apheresis or study product components~* Positive for HIV, hepatitis B or hepatitis C~* Active inflammatory or autoimmune disease, or chronic immunosuppressive state~* Drug abuse~* Pregnant or lactating~* Malignant neoplasm within 5 years~* History of Sickle Cell Disease~* Participation in another clinical study within 90 days

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Autologous CD34 cells (Type: EXPERIMENTAL): Open label active treatment arm. Subjects receive autologous CD34 cells.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Prospective Observational Study of Effect of Somatropin on Growth Hormone Deficient Adults

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~- Adult growth hormone deficiency as per the local Humatrope label and as judged by the attending physician~Exclusion Criteria:~- As per the local Humatrope label and as judged by the attending physician

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Somatropin replacement treatment (Type: None): Adult participants with growth hormone deficiency receiving somatropin replacement treatment.
- No treatment (Type: None): Adult participants with growth hormone deficiency receiving no somatropin replacement treatment.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: SPD503 (Guanfacine Hydrochloride) in ADHD Plus Oppositional Symptoms

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Healthy subjects with ADHD and oppositional symptoms~* ADHD-RS\>=24~* CGI \>=4~* T-score of Opp subscale CPRS-R:L \>=65~* Normal ECG and BP~* \>= 55 lbs

- Gender: ALL
- Minimum Age: 6 Years
- Maximum Age: 12 Years
- Healthy Volunteers: f

Study Arms:
- SPD503 (Guanfacine hydrochloride) (Type: EXPERIMENTAL): None
- Placebo (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Study to IDEntify Patients With Advanced/Metastatic Non Small Cell Lung Cancer (NSCLC) and ALK and ROS1 Translocation and to Establish Their Therapeutic Management (IDEALK&ROS)

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: OTHER
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~For ALK Incidence substudy~* Patients with Advanced or metastatic non-small cell lung cancer~* Patients who will be screened for anaplastic lymphoma kinase (ALK) rearrangement~* Age \> 18 years For ALK treatment substudy (retrospective and prospective)~* Age \> 18 years~* Confirmed anaplastic lymphoma kinase (ALK)-positive tumour~* Patients treated with crizotinib under routine clinical practice~* Patients with a minimum data registered at the medical history~* For the patients that will be recruited prospectively: Patients must have a signed informed consent document.~For the ROS1 treatment sub-study (retrospective only):~* Age \> 18 years~* Confirmation of NSCLC with ROS1-positive translocation~* Have been eligible to receive treatment with crizotinib according to routine clinical practice since the market launch of the ROS1 indication in Spain on 8 February 2017 until the opening of the site.~* Patients should have a predetermined minimum amount of data recorded in their medical records.~Exclusion Criteria:~* Any patient who does not meet any of the inclusion criteria defined in the previous section, depending on the sub-study for which they are included.

- Gender: ALL
- Minimum Age: 19 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Routine clinical practice group (NSCLC ALK+, ROS1) (Type: None): Patients diagnosed and treated following routine clinical practice, for their NSCLC ALK+ or ROS1

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete